FluoGuide A/S

FluoGuide, a Danish biotech startup founded in 2018, is making waves in the field of precision cancer surgery. Its flagship product, FG001, is a groundbreaking solution designed to improve surgical accuracy in cancer treatment. By using fluorescent light that binds to the widely expressed uPAR receptor in most solid cancer types, FG001 illuminates cancer cells intraoperatively, thus enhancing precision during surgery. The company anticipates that the use of FG001 will not only reduce the incidence of local recurrence after surgery and surgical complications but also ultimately lead to better treatment outcomes for patients while decreasing healthcare costs. Moreover, FluoGuide's innovative technology platform has the potential for broader applications, including photothermal therapy (PTT), which targets and kills cancer cells using near-infrared light. This technique has the added benefit of sparing healthy surrounding tissue from damage, thus directly contributing to improved patient outcomes. With a recent kr250.00M Post-IPO Equity investment by OP Financial Group, Linc AB, and Arbejdernes Landsbank on 10 March 2022, FluoGuide is poised for further growth and development. As a testament to its progress, FluoGuide is listed on the Nasdaq First North Growth Market in Stockholm under the ticker symbol "FLUO." For more information about FluoGuide's pipeline, technology, and upcoming events, visit www.fluoguide.com.